Faron Pharmaceuticals - Positive phase II BEXMAB topline results
Phase II BEXMAB trial met primary endpoint in treatment-resistant high-risk MDS with sustained high response rates.
vs expectations: in line
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
Redeye comments on Faron’s announcement that the phase II BEXMAB trial has met its primary endpoint in treatment-resistant high-risk MDS. We are encouraged to see topline results confirming earlier interim data, with sustained high response rates in this difficult-to-treat population and a continued strong safety profile. These findings not only validate bexmarilimab’s clinical potential but also support Faron’s regulatory and commercial strategy as the company prepares for pivotal phase III development.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.